grant

Contribution of CdiA to Pseudomonas aeruginosa pathobiology

Organization LOYOLA UNIVERSITY CHICAGOLocation MAYWOOD, UNITED STATESPosted 24 Jun 2021Deadline 31 May 2027
NIHUS FederalResearch GrantFY2025AffectAllelesAllelomorphsAntibiotic ResistanceAreaAttenuatedBacteremiaBacteriaBacteria resistanceBacteria resistantBacterial ToxinsBacterial resistantC-terminalCell BodyCell SurvivalCell ViabilityCellsCharacteristicsClinicalCodeCoding SystemCommon CoreComplexDNA mutationDataDefectDiseaseDisease ProgressionDisorderE coliE. coliEC 1.1.1.27Escherichia coliEukaryotic CellExcretory functionExotoxinsGeneralized GrowthGenesGenetic ChangeGenetic defectGenetic mutationGenomeGenomic approachGoalsGrantGrowthHeLaHealth CareHealth Care CostsHealth CostsHela CellsImmune Cell ActivationImmune systemIn VitroIncidenceInfectionInflammationIntoxicationL-Lactate DehydrogenaseL-Lactic Acid DehydrogenaseLaboratoriesLactate DehydrogenaseLength of StayLuciferase ImmunologicLuciferasesLytotoxicityMDR P aeruginosaMDR P. aeruginosaMDR Pseudomonas aeruginosaMeasuresMediatingMiceMice MammalsModelingMolecularMulti-Drug ResistanceMultidrug ResistanceMultiple Drug ResistanceMultiple Drug ResistantMurineMusMutationNAD-Lactate DehydrogenaseNumber of Days in HospitalOrganismOutcomeP aeruginosaP. aeruginosaP. aeruginosa infectionPathogenesisPathogenicityPathogenicity FactorsPathway interactionsPatientsPeptide DomainPneumoniaProkaryotaeProkaryotic CellsPropertyProtein DomainsProteinsPseudomonas aeruginosaPseudomonas aeruginosa infectionPseudomonas aeruginosa multi drug resistancePseudomonas pyocyaneaPublic HealthPyocyaninPyocyanineReporterReportingResearchResistance to Multi-drugResistance to MultidrugResistance to Multiple DrugResistance to antibioticsResistant to Multiple DrugResistant to antibioticsResistant to multi-drugResistant to multidrugRoleSamplingSurfaceSystemT3SSTertiary Protein StructureTestingTherapeuticTherapeutic AgentsTherapeutic InterventionTissue GrowthToxic effectToxicitiesToxinTransfectionTransfer RNATriplet Codon-Amino Acid AdaptorType III Secretion SystemType III Secretion System PathwayVirulenceVirulence FactorsVirulentWorkantagonismantagonistantibiotic drug resistanceantibiotic resistantattenuateattenuatesbacteraemiabacterial bloodstream infectionbacterial infection in the bloodstreambacterial resistancecombatcomparative genomicscytotoxicitydeath riskenhancing factorexcretiongenome mutationgenomic effortgenomic strategyhealth organizationhigh riskhospital dayshospital length of stayhospital stayimmune activationinfected with P. aeruginosainfected with Pseudomonas aeruginosainsightinterestintervention therapylactic acid dehydrogenaseliving systemmicroorganismmortality riskmulti-drug resistantmulti-drug resistant P. aeruginosamulti-drug resistant Pseudomonas aeruginosamultidrug resistantmultidrug resistant P. aeruginosamultidrug-resistant P. aeruginosamultidrug-resistant Pseudomonas aeruginosamutantnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetontogenypathwayprogramsprokaryoterational designresistance strainresistance to Bacteriaresistance to Bacterialresistant strainresistant to Bacteriaresistant to Bacterialsocial rolestemtRNAtargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttraittransfer Ribonucleic acidstype 3 secretion system
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Project Summary/Abstract
Pseudomonas aeruginosa is a leading cause of healthcare-acquired infections worldwide. Many globally-

distributed high-risk strains are emerging due to an increase in antibiotic resistance and acquisition of novel

virulence traits. With diminishing treatment options for many of these severe P. aeruginosa infections, studies

aimed at uncovering the virulence strategies used by these aggressive clinical strains should help to identify new

targets for therapeutic intervention. Our research program aims to elucidate virulence strategies that enhance

the pathogenicity of P. aeruginosa. We recently employed a comparative genomics approach to interrogate the

accessory genomes of 100 clinical isolates for potential factors that augment the virulence of P. aeruginosa. By

comparing virulence in a mouse infection model with the presence or absence of genes in the accessory genome,

we identified several virulence determinants enriched among highly virulent P. aeruginosa strains that were

absent from less virulent strains. From this work we identified an accessory virulence factor that spanned a

portion of two genes encoding products involved in contact-dependent growth inhibition (CDI). CDI is one type

of competitive mechanism microorganisms use to antagonize their immediate neighbors by delivering protein

toxins directly into targeted cells. This antagonism is executed by CdiA, a large multidomain exoprotein that sits

at the surface of an attacking cell and delivers a self-contained toxin domain into the targeted cell. The

importance of this proposal stems from our discovery that: (i) CdiA contains a toxin domain that has tRNAse

activity against prokaryotic and eukaryotic substrates, (ii) mutations that abrogate the in vitro tRNAse activity

attenuate both CDI and virulence in mice, (iii) the CdiA-toxin domain has cytopathic effects on eukaryotic cells

dependent upon its tRNase activity. To our knowledge this dule role for CdiA in both interbacterial completion

and virulence within a mammalian host has not yet been investigated for P. aeruginosa. From this preliminary

work we hypothesize that P. aeruginosa can utilize CdiA to intoxicate host cells for overcoming barriers to

infection. Our proposal seeks to answer a number of outstanding questions at the molecular (Aim 1), cellular

(Aim 2), and organismal (Aim 3) level. Successful completion of these aims will provide detailed insight into how

CdiA contributes to P. aeruginosa pathobiology.

Grant Number: 5R01AI163119-05
NIH Institute/Center: NIH

Principal Investigator: Jonathan Allen

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →